Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID 19 outpatients meta-analysis

O'Brien (Part B: recently infected asymptomatic patients), 2021
RCTcasirivimab and imdevimab (Ronapreve, REGN-COV2)placeboCOVID 19 outpatientssome concern
156/158 conclusif ")' style='color: black;' class='popover-interpretation' data-toggle='popover' data-placement='bottom' data-html='true' data-trigger='hover' container='body' data-content="

deaths efficacy

relative treatment effect [95% CI]: 1.01 [0.02; 51.05] calc.

0/155 (0.0%) vs. 0/156 (0.0%)
ARR=0.00% 95% CI [0.00; 0.00], NNT=-Infinity

" >1%
PINETREE (GS-US-540-9012), 2021
RCTremdesivirplaceboCOVID 19 outpatientslow
292/292 conclusif 1%
C3PO, 2020
RCTconvalescent plasma treatmentplaceboCOVID 19 outpatientssome concern
257/254 inconclusive 88%
Cov-2067 Weinreich (1200mg), 2020
RCTcasirivimab and imdevimab (Ronapreve, REGN-COV2)placeboCOVID 19 outpatientssome concern
838/840 conclusif -50%
1 study excluded by filtering options (1 RCT / 0 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).